Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 6/20 | 0.65 |
| ▸ | RAB9A | P51151 | 6/20 | 0.65 |
| ▸ | TP53 | P04637 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | ATM | Q13315 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | MGLL | Q99685 | 2/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.58 |
| ▸ | RELA | Q04206 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.54 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.54 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6191868 | 0.90 | NPC1 (0.57) | NPC1RAB9ATP53SMN1; SMN2ALDH1A1 | |
| SCHEMBL17797704 | 0.87 | NPC1 (0.52) | NPC1RAB9ATP53SMN1; SMN2ALDH1A1 | |
| SCHEMBL17813395 | 0.87 | NPC1 (0.52) | NPC1RAB9ATP53SMN1; SMN2ALDH1A1 | |
| SCHEMBL6212186 | 0.86 | BAZ2B (0.57) | NPC1RAB9ATP53SMN1; SMN2ALDH1A1 | |
| SCHEMBL17797663 | 0.86 | TMEM97 (0.55) | NPC1RAB9ATP53SMN1; SMN2ALDH1A1 | |
| SCHEMBL17797565 | 0.85 | TMEM97 (0.54) | NPC1RAB9ATP53SMN1; SMN2ALDH1A1 | |
| SCHEMBL14429561 | 0.84 | HRH3 (0.59) | NPC1RAB9ATP53SMN1; SMN2ALDH1A1 | |
| SCHEMBL30086241 | 0.84 | NPC1 (0.54) | NPC1RAB9ATP53SMN1; SMN2ALDH1A1 | |
| SCHEMBL26506778 | 0.84 | NPC1 (0.54) | NPC1RAB9ATP53SMN1; SMN2ALDH1A1 | |
| SCHEMBL4877801 | 0.84 | MAOA (0.54) | NPC1RAB9ATP53SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11091421-B2 | Benzene fused heterocyclic derivative and pharmaceutical composition comprising the same | TAIWANJ PHARMACEUTICALS CO., LTD. (TW) | 2021-08-17 | — | — | US | disclosed |
| US-20200190010-A1 | BENZENE FUSED HETEROCYCLIC DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | TAIWANJ PHARMACEUTICALS CO., LTD. (TW) | 2020-06-18 | — | — | US | disclosed |
| WO-2019051222-A1 | BENZENE FUSED HETEROCYCLIC DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | TAIWANJ PHARMACEUTICALS CO., LTD. (TW) | 2019-03-14 | — | — | WO | disclosed |
| US-5225565-A | Antibacterial 3-(fused-ring substituted)phenyl-5β-amidomethyloxazolidin-2-ones | THE UPJOHN COMPANY (US) | 1993-07-06 | — | — | US | disclosed |
| US-5182403-A | Bactericides, treatment of AIDS | THE UPJOHN COMPANY (US) | 1993-01-26 | — | — | US | disclosed |
| US-5164510-A | Bactericides | THE UPJOHN COMPANY (US) | 1992-11-17 | — | — | US | disclosed |
| EP-0434714-A1 | IN POSITION 3 SUBSTITUTED-5-BETA-AMIDOMETHYL-OXAZOLIDIN-2-ONES | THE UPJOHN COMPANY (US) | 1991-07-03 | — | — | EP | disclosed |
| WO-1990002744-A1 | IN POSITION 3 SUBSTITUTED-5-BETA-AMIDOMETHYL-OXAZOLIDIN-2-ONES | THE UPJOHN COMPANY (US) | 1990-03-22 | — | — | WO | disclosed |
| EP-0359418-A1 | 5'-Indolinyl-5beta-amidomethyloxazolidin-2-ones, 3-(fused-ring substituted)phenyl-5beta-amidomethyloxazolidin-2-ones and 3-(nitrogen substituted)phenyl-5beta-amidomethyloxazolidin-2-ones | THE UPJOHN COMPANY (US) | 1990-03-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11091421-B2 | Benzene fused heterocyclic derivative and pharmaceutical composition comprising the same | RORB, RORC, NR3C1 | NPC1 2271/4885RAB9A 2336/4885TP53 2486/4885 |
| US-20200190010-A1 | BENZENE FUSED HETEROCYCLIC DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | RORB, RORC, NR3C1 | NPC1 2271/4885RAB9A 2336/4885TP53 2486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.